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Abstract
Background: We examined whether impaired renal function causes thickening of the aortic valve
leaflets in hyperlipidemic apoE-knockout (apoE-/-) mice, and whether the putative effect on the
aortic valves could be prevented by inhibiting the angiotensin-converting enzyme (ACE) with
enalapril.
Methods: Thickening of the aortic valve leaflets in apoE-/- mice was induced by producing mild or
moderate chronic renal failure resulting from unilateral nephrectomy (1/2 NX, n = 18) or subtotal
nephrectomy (5/6 NX, n = 22), respectively. Additionally, the 5/6 NX mice were randomized to
no treatment (n = 8) or enalapril treatment (n = 13). The maximal thickness of each leaflet was
measured from histological sections of the aortic roots.
Results: Leaflet thickness was significantly greater in the 5/6 NX mice than in the 1/2 NX mice (P
= 0.030) or the unoperated mice (P = 0.003). The 5/6 NX mice treated with enalapril had
significantly thinner leaflets than did the untreated 5/6 NX mice (P = 0.014).
Conclusion: Moderate uremia causes thickening of the aortic valves in apoE-/- mice, which can be
attenuated by ACE inhibition. The nephrectomized apoE-/- mouse constitutes a new model for
investigating the mechanisms of uremia-induced aortic valve disease, and also provides an
opportunity to study its pharmacologic prevention.
Background
The prevalence of cardiovascular disease (CVD) is far
greater in patients with chronic renal failure (CRF) than in
the general population [1]. Similarly, the progression of
aortic stenosis (AS) is accelerated in chronically uremic
patients [2-4]. In addition to renal failure, epidemiologi-
cal studies have identified that other atherosclerotic risk
factors, including hypertension, smoking, hypercholester-
olemia, diabetes mellitus, male gender, and age, predis-
pose to AS development [5-7]. Stenotic aortic valves are
characterized by an atherosclerosis-like lesion, consisting
of inflammatory cells, cholesterol deposits, and calcified
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nodules [8]. Furthermore, active bone formation and
adverse extracellular matrix remodeling contribute to the
thickening and stiffening of the valves [9-11]. Impor-
tantly, angiotensin-converting enzyme (ACE), angi-
otensin II (Ang II), and Ang II type 1 receptors (AT-1Rs)
are expressed in the aortic valves and ACE activity is aug-
mented in the stenotic valves [12,13], suggesting that
inappropriate activation of the renin-angiotensin system
(RAS) participates in the pathogenesis of AS. To fully
understand the pathogenic mechanisms of AS and eventu-
ally to be able to design potential drug therapies, animal
models suitable for preclinical studies of AS are needed.
To date, several rabbit models of AS have been introduced
[14-17]. In addition, different mouse models of AS have
been tested. These include old apoE-/- mice [18] and old
LDLr-/- apoB100/100 mice [19], which are prone to develop
functional valvular heart disease, and wild-type mice in
which a high fat/high carbohydrate diet was shown to trig-
ger thickening of the aortic valve leaflets [20].
In view of the higher prevalence of aortic valve calcifica-
tion and stenosis among patients with renal failure, and
the pathogenetic similarities between AS and atheroscle-
rosis, we hypothesized that chronic uremia would cause
aortic valve thickening, a condition known to ultimately
lead to functional impairment and AS development. We
chose the nephrectomized apoE-/- mouse, which develops
extensive vascular disease and is already an established
animal model in the study of uremic atherosclerosis
[21,22] and could thus serve as a suitable model of ure-
mia-induced AS. Moreover, to learn whether Ang II-
dependent pathways may contribute to uremia-associated
aortic valve thickening, we tested the effect of enalapril, an
ACE inhibitor, on valvular thickening in this particular
mouse model.
Methods
Animals
We examined the valvular leaflets in hearts from mice that
were also used to study the effects of uremia on the devel-
opment of atherosclerosis [21,22]. The studies were per-
formed according to the principles stated in the Danish
law on animal experiments and approved by the Animal
Experiments Inspectorate, Ministry of Justice, Denmark.
The animals were male apoE-/-  mice (C57BL/6JBom-
ApoEtm1Unc), which had been backcrossed 10 generations
onto the C57BL/6 background (M&B Laboratory Animals
and Services for Biomedical Research, Ry, Denmark) and
fed with a standard mouse diet (Altromin 1314, Altromin,
Lage, Germany). The investigation was divided into two
substudies, which are referred to as Study 1 and Study 2 in
the text. The study design of both studies is shown in Fig-
ure 1.
In Study 1, the mice were assigned at the age of seven
weeks to one of three groups: (1) unoperated (0 NX, n =
13), (2) unilateral nephrectomy (1/2 NX, n = 18) in which
the left kidney was removed, or (3) subtotal nephrectomy
(5/6 NX, n = 22) in which both the left kidney and the
upper and lower poles of the right kidney were resected.
The surgery was performed under anesthesia with postop-
erative analgetics as previously described [21]. The mice
were sacrificed 22 weeks after allocation to the different
groups, and the portion of the heart containing the proxi-
mal ascending aorta was removed, fixed in formalin and
embedded in paraffin [21].
Flowcharts showing the study designs in Study 1 and Study 2 Figure 1
Flowcharts showing the study designs in Study 1 and Study 2.
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In Study 2, the mice were allocated at the age of 10 weeks
to either 5/6 NX or a sham operation (0 NX). In the 5/6
NX group, the upper and lower poles of the right kidney
were resected, and two weeks later the entire left kidney
was resected [22]. The sham-operated mice underwent
kidney exposure operations at the same time points. To
study the effect of ACE inhibition on the development of
aortic valve thickening, treatment with an ACE inhibitor
(2 mg/kg/d enalapril) was started four weeks after
nephrectomy. After 36 weeks of uremia, the mice were
sacrificed and the tissues were snap frozen, thawed, and
fixed in formalin, after which they were embedded in Tis-
sue-Tek OCT (Sakura Finetek Europe B.V., Zoeterwoude,
The Netherlands) and frozen again [22].
Measurements of body weight, blood pressure, blood
hemoglobin, the plasma levels of urea, creatinine, phos-
phate, calcium, cholesterol, and triglycerides were per-
formed as previously described [21,22].
Histology
In Study 1, 4-μm-thick sections were cut from the paraffin-
embedded blocks, beginning at the apex of the heart. Col-
lection of the sections was started when leaflet commis-
sures first appeared, and then continued to include the
first 160 μm of the aortic root (see Figure 2A–C). In Study
2, 8-μm-thick frozen sections were cut, beginning at the
apex of the heart. Collection of the sections was started
once three leaflets became visible, and then continued to
include the first 240 μm of the aortic root.
Hematoxylin-stained histological sections derived from
both studies were photographed with a digital camera
(SPOT RT, Diagnostic Instruments Inc., Sterling Heights,
MI, USA) attached to a Nikon E600 (Nikon Corp., Tokyo,
Japan) light microscope. The sections were coded so that
the observer (M.A.S.) was blinded. Six sections from each
mouse were photographed at 10× magnification. Maxi-
mal leaflet thickness was measured at the nodule of Aran-
tius in the middle of each leaflet (see Figure 3B and Figure
4A–F) with Image-Pro Plus 6.1.0.346 (Media Cybernetics
Inc., Silver Spring, MD, USA) software [20]. The thickness
of the aortic valve leaflets in each mouse was defined as
the average of the three largest leaflet thicknesses meas-
ured in the six sections. The total cross-sectional areas of
the aortic valve leaflets were measured from three sections
per mouse using the Image-Pro Plus software (see Figure
3C). The aortic atherosclerotic en face plaque areas have
been assessed previously for Study 1 [21] and Study 2
[22].
For Oil Red O staining, the sectioned samples were fixed
with paraformaldehyde, washed, and dehydrated in pro-
pylene glycol. Thereafter the samples were incubated with
Histological cross-sections of the aortic root showing three  levels of cutting of the aortic valve Figure 2
Histological cross-sections of the aortic root showing 
three levels of cutting of the aortic valve. The sections 
were chosen to show (A) the commissural level (0 μm), and 
the levels (B) -80 μm and (C) -160 μm towards the base of 
aortic valve. Note that at 0 μm, only the leaflet commissures 
are visible, demonstrating that the free edge of the leaflet is 
below the 0 μm level. The maximal leaflet thickness (meas-
ured at the nodule of Arantius located at the center of a leaf-
let) is smaller at -160 μm than at -80 μm, reflecting the 
gradual thickening of the nodule towards the free edge of the 
leaflet. The sections were collected starting from the base of 
the valve and moving towards the commissural level, which is 
defined as the reference level (0 μm) in this stack of sections. 
Panel (D) illustrates the cutting levels in the aortic root. The 
sample is derived from a uremic mouse (Study 1). Photo-
graphed using 4× magnification.BMC Cardiovascular Disorders 2009, 9:10 http://www.biomedcentral.com/1471-2261/9/10
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O0625 stain (Sigma-Aldrich Corporation, Saint Louis,
MO, USA) and differentiated in propylene glycol. Coun-
terstaining was done with Harris's hematoxylin (Merck &
Co. Inc., Whitehouse Station, NJ, USA). Masson's tri-
chrome staining was done according to the standard
method, modified by Lillie, using a Sigma-Aldrich HT15
kit.
Statistics
Differences between groups were evaluated by Kruskal-
Wallis test and two-group comparisons by Mann-Whitney
U test unless specified otherwise. Spearman's (non-para-
metric data) and Pearson's (parametric data) correlation
coefficients were used to assess relationships between
continuous variables. Statistical analyses were performed
using SPSS 15.0 for Windows (SPSS Inc., Chicago, IL,
USA). P-values of < 0.05 were considered statistically sig-
nificant. Data are expressed as mean ± standard deviation
(SD).
Results
Effects of uremia and enalapril treatment on plasma 
biochemistry, body weight, blood pressure, and aortic 
atherosclerosis
Subtotal nephrectomy (5/6 NX) caused 2.4- to 2.6-fold
increases in plasma urea concentrations and affected
blood hemoglobin, plasma calcium × phosphate product,
plasma cholesterol, and body weight (see Tables 1 and 2).
Unilateral nephrectomy (1/2 NX) produced parallel but
less pronounced effects (see Table 1). Mean systolic arte-
rial blood pressure was not affected by 5/6 NX. As previ-
ously reported [21], 5/6 NX causes a massive increase in
aortic atherosclerosis lesion areas. Similar effects were
observed in both Study 1 and Study 2. Furthermore, in
Study 2, enalapril decreased plasma cholesterol concen-
tration, aortic atherosclerotic lesional area fraction, and
systolic arterial blood pressure (see Table 2).
Effect of uremia on aortic valve leaflet thickening in 
unoperated, 1/2 NX, and 5/6 NX apoE-/- mice (Study 1 and 
Study 2)
After exposure to uremia, the aortic leaflets appeared
thickened and the leaflet thickening was diffuse, with
maximal thickening located in the central third of the leaf-
let. To quantitate the effect of renal insufficiency on aortic
valve thickening, we measured the maximal aortic valve
leaflet thickness at the valve nodule in the nephrect-
omized and control mice. The analysis of leaflet thickness
in the mice exposed to uremia for 22 weeks (Study 1)
revealed that the thickness of the aortic valve leaflets was
significantly greater in the 5/6 NX mice (145 ± 31 μm)
than in the 1/2 NX mice (121 ± 31 μm, P = 0.030) or
unoperated mice (106 ± 45 μm, P = 0.003) (see Figure
5A). Also, there was a strong correlation between aortic
lesional area and aortic valve leaflet thickness (n = 21,
Spearman's r = 0.67, P = 0.0009) in the 5/6 NX mice (see
Figure 6A). Moreover, plasma creatinine correlated posi-
tively with aortic valve leaflet thickness (n = 20, Spear-
man's r = 0.48, P = 0.034) in the 5/6 NX mice (see Figure
6B). Analysis of leaflet thickness in the mice exposed to
uremia for 36 weeks (Study 2) showed a trend of uremia-
induced aortic valve thickening, although the result was
not statistically significant due to the small number of
mice. There was a strong linear correlation between the
thickness of the aortic valve leaflets and the total cross-sec-
tional area (P = 0.00000037) (see Figure 3).
Effect of enalapril on aortic valve leaflet thickening in 5/6 
NX apoE-/- mice (Study 2)
After 36 weeks of uremia, we examined the effect of ACE
inhibition on maximal valve thickness in the 5/6 NX
apoE-/- mice. The 5/6 NX mice that had been treated with
2 mg/kg/d enalapril for 32 weeks had significantly thinner
aortic valve leaflets when compared with the 5/6 NX mice
Correlation between the thickness and total cross-sectional  area of the aortic valve leaflets Figure 3
Correlation between the thickness and total cross-
sectional area of the aortic valve leaflets. In the graphi-
cal presentation (A), each point denotes one mouse (Study 
2). The thickness of the aortic valve leaflets is the average 
value of the three thickest leaflets in six sections per mouse. 
The total cross-sectional area of the aortic valve leaflets is 
the average value of three sections per mouse. Panels B and 
C show typical sections from which the measurements were 
made. In panel (B), each bar denotes the maximal thickness 
of a leaflet, and in panel (C) the red color shows the area 
measured to obtain the total area of the three leaflets in one 
section. N-value, Spearman's correlation coefficient, and P-
value are shown.
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that had not been treated with enalapril (159 ± 67 μm vs.
261 ± 88 μm, P = 0.014) (see Figure 5B)
Histopathologic findings (Study 2)
To examine for the presence of fibrous and neutral lipid
components in the valves, the sections were stained with
Massons's trichrome and Oil Red O, respectively. As
shown in Figure 4G–I, the valvular leaflets in all three
groups contained collagen. In the thickened leaflets, there
was not only more collagen, but the collagen bundles
formed dense deposits, reflecting fibrous thickening of
the valves. The leaflets of the 5/6 NX mice treated with
enalapril appeared to contain less collagen than the leaf-
lets of their untreated littermates, and the collagen bun-
dles were arranged in a looser fashion.
Since all the animals in this animal model of aortic valvu-
lar thickening were hyperlipidemic apoE-/- mice, their aor-
tas contained atherosclerotic plaques (see Tables 1 and 2).
As expected, also the aortic wall in the aortic root region
contained Oil Red O-positive intimal thickenings (see Fig-
ure 4J–L). In sharp contrast, Oil Red O staining was nega-
tive in the leaflets, demonstrating that, despite the
presence of marked hyperlipidemia and uremia, the val-
vular pathology did not involve deposition of neutral lip-
ids, i.e. cholesteryl esters or triglycerides, in the leaflets.
Discussion
The present study demonstrates that uremia accelerates
aortic valve thickening in genetically hyperlipidemic
mice. Importantly, aortic valve thickening in the nephrec-
tomized mice was inhibited by enalapril, suggesting that
uremia induces aortic valve sclerosis or stenosis via Ang II-
mediated mechanisms. These findings emphasize the sig-
nificance of local RAS in the pathobiology of aortic valve
disease and raise pharmacological prevention of RAS
actions as a potential treatment option in this disease.
Indeed, recent investigations have portrayed the possibil-
ity that activation of RAS promotes AS progression and,
thus, inhibition of its actions may be beneficial in this dis-
ease [23]. ACE is locally produced in aortic valves and its
enzymatic activity is augmented in stenotic leaflets [13].
Furthermore, Ang II and profibrotic Ang II type 1 recep-
tors (AT-1Rs) are present in diseased valves and colocalize
with ACE in valvular lesions [12,13]. In addition to ACE,
two alternative Ang II-forming enzymes, namely chymase
and cathepsin G, are upregulated in stenotic valves, fur-
ther enhancing the Ang II-forming potential of the
affected valves [10,13]. Accordingly, Ang II, as a powerful
proinflammatory and profibrotic mediator [24], may par-
ticipate in the pathogenesis of AS both in subjects with
preserved renal function and, as suggested by the present
results, also in uremic patients. Preliminary support for
the benefit of ACE inhibitors in AS patients originates
from small clinical studies in which ACE inhibitors have
been shown to be well tolerated in AS patients and to even
improve their hemodynamic status and exercise tolerance
[25-27]. Moreover, in a recent retrospective study by
O'Brien and co-workers, the use of ACE inhibitors was
associated with slower progression of aortic valve calcifi-
cation [28]. In contrast, Rosenhek and co-workers were
not able to demonstrate any beneficial effects of ACE
inhibitors on the hemodynamic progression of AS [29].
Considering the retrospective nature and small sample
sizes of these trials, additional research in this area is
indispensable.
Histological  sections showing valvular thickness, and stain- ings of the valves for the detection of fibrosis and neutral lip- ids in variously treated apoE-/- mice Figure 4
Histological  sections showing valvular thickness, and 
stainings of the valves for the detection of fibrosis 
and neutral lipids in variously treated apoE-/- mice. 
Typical hematoxylin-stained sections from (A) unoperated 
controls (0 NX), (B) unilaterally nephrectomized (1/2 NX), 
and (C) subtotally nephrectomized (5/6 NX) apoE-/- mice in 
Study 1, and (D) sham-operated controls (0 NX), (E) subto-
tally nephrectomized and (F) subtotally nephrectomized enal-
april-treated (5/6 NX, Enalapril) apoE-/- mice in Study 2. Each 
bar denotes the maximal thickness of a leaflet. Masson's tri-
chrome stainings from (G) control, (H) subtotally nephrect-
omized and (I) subtotally nephrectomized enalapril-treated 
apoE-/- mice show the presence of blue-colored collagen in 
the leaflets. Note the massive amount of fibrosis in the 
nephrectomized untreated mice compared with the mild 
fibrosis of the nephrectomized enalapril-treated mice. Oil 
Red O stainings from (J) control, (K) subtotally nephrect-
omized and (L) subtotally nephrectomized enalapril-treated 
apoE-/- mice. The red lipid staining is present in the athero-
sclerotic plaques of the aortic wall, but absent from the valve 
leaflets. Because luminal acellular and unwashable masses are 
present in (K), the borders of the leaflet are denoted with 
black arrowheads. Photographed using 10× (A-F) and 20× 
(G-L) magnification.BMC Cardiovascular Disorders 2009, 9:10 http://www.biomedcentral.com/1471-2261/9/10
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In epidemiological studies, the prevalence of aortic valve
abnormalities, including valve sclerosis, calcification, and
stenosis, is increased in patients with renal failure [30-32].
Moreover, in patients with renal insufficiency, the rate of
AS progression is higher than in those with normal renal
function [3,33]. In view of these observations, chronic
uremia and its consequences seem to exert detrimental
effects on the aortic valve leaflets. Several uremia-related
mechanisms may contribute to the thickening of the aor-
tic valve leaflets. Renal failure is associated with abnormal
calcium-phosphate homeostasis, including hyperphos-
phatemia, a high serum calcium phosphate product, and
secondary hyperpharathyroidism, which may lead to met-
astatic calcification of tissues, including the aortic valve
leaflets [3,34]. Furthermore, chronic renal insufficiency
leads to activation of RAS [35], which constitutes a risk
factor of cardiovascular calcification in humans. Bilateral
total nephrectomy (6/6 NX) in rats has been shown to
cause plasma renin to fall below the limits of detection
within 24–48 hours, thus effectively eliminating circulat-
ing RAS [36]. Because of the massive reduction in kidney
tissue, it is also likely that the levels of circulating renin
were decreased in the 5/6 nephrectomized mice in the
present study, as well. However, ACE is produced mainly
in the vascular bed of the lungs [37]. According to our pre-
viously published results, 5/6 nephrectomy increases
plasma ACE activity by 36 percent [22]. Thus, inhibition
of ACE should be an effective and appropriate treatment
strategy in the present animal model.
In addition to the mouse models described above, several
rabbit models of AS have been introduced [14-17]. Raja-
mannan and co-workers described a hypercholestero-
lemic rabbit model in which hypercholesterolemia
resulted in aortic valve thickening, atherosclerotic
changes, and bone matrix production in the valves, and
these adverse processes were prevented by atorvastatin
[15,38,39]. In contrast, in the rabbit model described by
Drolet and co-workers, hypercholesterolemia alone did
not cause any significant functional aortic valve abnor-
mality when assessed by echocardiography [16]. Instead,
hypercholesterolemia combined with toxic doses of vita-
min D resulted in decreased aortic valve area (AVA) and
increased transvalvular gradients in these animals [16]. In
a recent rabbit model of AS, hypercholesterolemia
induced fatty deposition, macrophage accumulation, and
osteopontin expression in the aortic valves, and these
atherosclerotic changes and expression of osteoblastic fac-
tors were attenuated by the AT-1R antagonist olmesartan
[17]. Furthermore, dietary hypercholesterolemia dis-
rupted endothelial integrity in lesion-prone areas of the
valves, whereas preservation of the endothelium was
attained with olmesartan [17]. These observations indi-
cate that aortic valve lesion development caused by hyper-
cholesterolemia is not only related to cholesterol
accumulation. Instead, activation of RAS appears as a key
element in lesion development, including both induction
of inflammation and osteoblastic transdifferentiation of
valvular cells.
The exact molecular mechanism by which enalapril pre-
vents aortic valve leaflet thickening remains unknown.
Besides being capable of inhibiting ACE enzyme locally,
enalapril is also able to exert multiple systemic effects. The
only statistically significant changes in metabolic indices
due to the enalapril treatment were lowering of systolic
blood pressure and plasma total cholesterol. Interestingly,
a recent study in humans has shown that ACE inhibitors
may have a beneficial effect on the lipid profile [40]. How-
ever, the very recently published SEAS study has clearly
shown that even a long-lasting lowering of the plasma
cholesterol level by 60 percent fails to affect the progres-
Table 1: Effect of chronic renal failure on body weight, blood pressure, blood hemoglobin, plasma indices of uremia, plasma lipids, and 
aortic atherosclerosis in Study 1.
Study 1
Unoperated (0 NX) 1/2 NX 5/6 NX
Variable Unit (n = 13) (n = 18) (n = 22) P
Body weight g 26.4 ± 1.6 27.6 ± 1.5 23.0 ± 3.5a < 0.0001
Mean blood pressure mmHg 116.6 ± 6.5 113.0 ± 8.2 116.8 ± 14.3 NS
B-hemoglobin mmol/L 8.38 ± 0.55 8.26 ± 0.26 6.85 ± 0.74a < 0.0001
P-urea mmol/L 10.6 ± 1.5 12.5 ± 2.1a 28.0 ± 9.7a < 0.0001
P-creatinine mmol/L 0.036 ± 0.005 0.038 ± 0.005 0.051 ± 0.007a < 0.0001
P-phosphate mmol/L 2.20 ± 0.16 1.89 ± 0.27a 2.61 ± 0.72a < 0.0005
P-calcium mmol/L 2.22 ± 0.12 2.25 ± 0.06 2.52 ± 0.12a < 0.0001
P-Ca × P mmol2/L2 4.89 ± 0.43 4.24 ± 0.64a 6.56 ± 1.82a < 0.0001
P-cholesterol mmol/L 13.3 ± 1.9 15.0 ± 3.6 19.3 ± 3.6a < 0.0001
Triglyceride mmol/L 0.70 ± 0.37 0.58 ± 0.20 0.46 ± 0.14a < 0.01
Aortic plaque area fraction % 0.048 ± 0.025 0.085 ± 0.038a 0.258 ± 0.117a < 0.0001
Fasting blood samples were obtained at the end of the study, i.e. when the mice were 29 weeks of age. Aortic plaque area fraction was determined 
by the en face technique. Values are mean ± SD. P-values were calculated using the Kruskal-Wallis test for differences between three groups. Two-
group comparisons were performed using the t-test. Statistically significant difference vs. "Unoperated" group is denoted by superscript a.BMC Cardiovascular Disorders 2009, 9:10 http://www.biomedcentral.com/1471-2261/9/10
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sion of aortic stenosis [41]. Importantly, enalapril may
contribute to the inhibition of valvular thickening also by
lowering systolic blood pressure. Excluding this possibil-
ity remains a challenge for future studies.
No animal model for uremia-induced aortic valve thick-
ening has been published previously. In the present study,
the increased prevalence of aortic valve leaflet thickening
among the hyperlipidemic mice with unilateral nephrec-
tomy, and consequently mild renal impairment, suggests
that even mild renal insufficiency promotes aortic valve
leaflet thickening and eventually may increase the risk of
aortic stenosis in hyperlipidemic mice. Importantly, in the
5/6 nephrectomized uremic mice, we noted that 22 weeks
of uremia (Study 1) induced less thickening of the leaflets
than did 36 weeks of uremia (Study 2), providing addi-
tional support for the idea that uremia induces gradual
valve thickening in this hyperlipidemic mouse model.
Furthermore, a strong correlation appeared between aor-
tic atherosclerotic lesional area and aortic valve thickness
(see Figure 6A). This is of interest, since epidemiological
studies have shown that AS and arterial atherosclerosis
share common risk factors, including uremia, hypercho-
lesterolemia, hypertension, smoking, diabetes, age, and
male gender [5-7]. Furthermore, coronary artery disease
coexists in approximately 50% of patients with AS [42],
and even patients with aortic valve sclerosis, an early stage
of AS, possess an elevated risk of myocardial infarction
and cardiovascular death [43]. Also, there was a signifi-
cant correlation between plasma creatinine level and aor-
tic valve thickness (see Figure 6B). Creatinine, being the
marker of renal dysfunction, suggests that uremia is an
important etiological factor of aortic valve thickening in
this particular model.
The following facts could be considered as limitations of
this study. The blood pressure-lowering effect of enalapril
may have contributed to the decreased thickening of the
valve leaflets. Although we demonstrate here that enal-
april prevents aortic valve thickening in nephrectomized
apoE-/- mice, we do not provide evidence concerning the
efficacy of enalapril in other mouse models of AS. Appro-
priate animal models of AS that closely mimic the disease
etiology and manifestations in humans are difficult to
establish, and the utilized models have several limita-
tions. In this sense, the present model of uremic apoE-/-
mice has the advantage of sharing the same etiology with
human AS in patients whose aortic valve disease is associ-
ated with chronic renal failure and hypercholesterolemia.
Previously, several mouse models of AS have been tested,
i.e. senile apoE-/- mice [18], LDLr-/- apoB100/100 mice [19],
nephrectomized fetuin-A-knockout mice with a high
phosphate diet [44], and wild-type mice fed a high fat/
high carbohydrate diet [20]. The general problem in
mouse models is the difficulty in assessing functional
impairment in the valve, i.e. challenging echocardiogra-
phy. In the present study, aortic valve echocardiography
was not part of the study design, as the focus was placed
on early histopathological changes in the valves, i.e. at a
stage in which no significant functional impairment of the
valves was to be expected (22 weeks in Study 1 and 36
weeks in Study 2). Indeed, previous models have
Table 2: Effects of chronic uremia and enalapril treatment on body weight, blood pressure, blood hemoglobin, plasma indices of 
uremia, plasma cholesterol, and aortic atherosclerosis in Study 2.
Study 2
Sham operation
(0 NX)
5/6 NX
No enalapril Enalapril
Variable Unit (n = 7) (n = 8) (n = 13) P
Body weight g 32.1 ± 2.0 27.3 ± 2.1a 27.4 ± 2.0 < 0.001
Systolic blood pressure mmHg 112.9 ± 6.1 116.8 ± 4.6 105.2 ± 7.2b < 0.005
B-hemoglobin mmol/L 9.60 ± 0.83 7.31 ± 0.97a 6.99 ± 0.66 < 0.001
P-urea mmol/L 11.9 ± 1.1 28.6 ± 5.4a 26.3 ± 6.2 < 0.001
P-creatinine mmol/L 0.016 ± 0.002 0.030 ± 0.007a 0.025 ± 0.006 < 0.001
P-phosphate mmol/L 2.47 ± 0.47 2.78 ± 0.65 2.54 ± 0.39 NS
P-calcium mmol/L 2.70 ± 0.21 2.95 ± 0.41 2.61 ± 0.07 < 0.05
P-Ca × P mmol2/L2 6.65 ± 1.45 8.40 ± 3.19 6.63 ± 0.99 NS
P-cholesterol mmol/L 16.3 ± 2.4 16.6 ± 3.3 13.5 ± 2.9b < 0.05
Aortic plaque area fraction % 0.10 ± 0.07 0.23 ± 0.08a 0.11 ± 0.04b < 0.005
Fasting blood samples obtained at the end of the study, i.e. when the animals were 46 weeks of age. Aortic plaque area fraction was determined by 
the en face technique. Enalapril was administered for 32 weeks with a dose of 2 mg/kg/d starting 4 weeks after the 5/6 nephrectomy. Values are 
mean ± SD. P-values were calculated using the Kruskal-Wallis test for differences between three groups. Two-group comparisons were performed 
using the t-test. Statistically significant difference vs. "Sham operation" group is denoted by superscript a. Statistically significant difference vs. "5/6 
NX, No enalapril" group is denoted by superscript b.BMC Cardiovascular Disorders 2009, 9:10 http://www.biomedcentral.com/1471-2261/9/10
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described functional changes only in older animals, and
echocardiac abnormalities were not evident in the apoE-/-
mice studied by Tanaka and co-workers until 80–120
weeks of age [18]. Finally, the duration of uremia was dif-
ferent in the two studies (22 weeks in Study 1 vs. 36 weeks
in Study 2). However, aortic valve thickening was
observed in both studies.
Conclusion
The present study demonstrates a novel mouse model of
aortic valve thickening, the uremic apoE-/- mouse, and
reveals a potential treatment of uremia-induced valvular
pathology by an ACE inhibitor. Although the mice were
severely hyperlipidemic and atherosclerotic, aortic valve
thickening presented itself as a fibrotic disease, not a lipid
disease. As aortic valve thickening represents an early stage
of AS, this animal constitutes a model for exploring the
development and pathogenesis of AS and its treatment by
pharmacological therapy, particularly with drugs that
inhibit the production and pathological effects of Ang II.
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